Amanda Hardy
Family · Alexander City, ALNPI 1174051643
Payments from drug & device makers
Across 192 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$504
- Lilly USA, LLC$436
- Novo Nordisk$436
- Amgen$332
- AstraZeneca$281
- GSK$275
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,468100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,468 in reported general payments places this provider in the 85th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 93 | $131,702 |
| MounjaroTirzepatide | 63 | $87,699 |
| EliquisApixaban | 89 | $66,242 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $43,529 |
| TrulicityDulaglutide | 24 | $39,509 |
| VraylarCariprazine Hcl | 23 | $37,699 |
| RybelsusSemaglutide | 25 | $36,510 |
| Repatha SureclickEvolocumab | 49 | $30,163 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $28,374 |
| XareltoRivaroxaban | 31 | $28,129 |
| LinzessLinaclotide | 30 | $26,261 |
| MyrbetriqMirabegron | 25 | $21,170 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 22 | $15,293 |
| Repatha SyringeEvolocumab | 13 | $14,842 |
| TradjentaLinagliptin | 11 | $13,462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $436 | $168,212118 claims |
| Lilly USA, LLCMounjaro, Trulicity | $436 | $127,20887 claims |
| PfizerEliquis | $66 | $66,24289 claims |
| AbbVieVraylar, Linzess | $504 | $63,96053 claims |
| GSKTrelegy Ellipta | $275 | $43,52957 claims |
| Boehringer IngelheimCombivent Respimat, Tradjenta, Jardiance | $110 | $41,75249 claims |
| AstraZenecaBreztri Aerosphere | $281 | $28,37434 claims |
| Johnson & JohnsonXarelto | $116 | $28,12931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,415 family providers in Alabama.
Other family in Alexander City
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.